Engrave Wealth Partners LLC Reduces Stake in Johnson & Johnson

Engrave Wealth Partners LLC, a financial institution, has sold 4.2% of its position in Johnson & Johnson (JNJ – Free Report) during the second quarter of this year. The company now owns 23,777 shares of Johnson & Johnson’s stock, making it the 16th largest holding in its portfolio. The value of Engrave Wealth Partners LLC’s holdings in Johnson & Johnson at the end of the reporting period was $3,936,000.

Other institutional investors have also made changes to their stakes in Johnson & Johnson. Atlantic Private Wealth LLC acquired a new position in the company during the first quarter, while GW&K Investment Management LLC, Dark Forest Capital Management LP, Ruedi Wealth Management Inc., and Kepos Capital LP added to their holdings during the fourth quarter.

Johnson & Johnson’s stock price declined by 1.4% on Friday, opening at $161.43. The company’s stock has fluctuated between $150.11 and $181.04 over the past year. Johnson & Johnson has a current ratio of 1.12, a quick ratio of 0.88, and a debt-to-equity ratio of 0.44. The company has a market capitalization of $419.55 billion and a price-to-earnings ratio of 32.68. The firm’s fifty-day simple moving average is $166.17, while its two-hundred-day simple moving average is $161.67.

Johnson & Johnson reported $2.80 earnings per share for the second quarter, surpassing the consensus estimate of $2.62. The firm’s quarterly revenue was $25.53 billion, beating the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%.

The company recently announced a quarterly dividend of $1.19 per share, which was paid on September 7th to shareholders of record on August 28th. This represents an annualized dividend of $4.76 and a yield of 2.95%. Johnson & Johnson’s payout ratio is 96.36%.

Company insiders, including William Hait and Peter Fasolo, have sold a significant number of shares. Analysts have set new price targets for the stock, with Raymond James, Atlantic Securities, and Stifel Nicolaus issuing positive ratings.

Johnson & Johnson, a healthcare company, develops, manufactures, and sells various products worldwide. Its subsidiaries include well-known brands such as AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, OGX, and JOHNSON’S, which offer a range of consumer health and beauty products.

– [MarketWatch](https://www.marketwatch.com/story/envestnet-asset-management-inc-purchases-7682-shares-of-johnson-johnson-jnj-2021-09-23)
– [Seeking Alpha](https://seekingalpha.com/news/3755685-Reasons-for-Johnson-and-Johnsons-share-price-decline)
– [The Motley Fool](https://www.fool.com/investing/2021/09/24/heres-why-johnson-johnson-is-falling-on-friday/)